Last updated: 4 January 2024 at 6:00pm EST

Nir Naor Net Worth

What's Nir Naor's mailing address?

Nir's mailing address filed with the SEC is 13631 PROGRESS BLVD.,, SUITE 400, ALACHUA, FL, 32615.

Insiders trading at Brainstorm Cell Therapeutics

Over the last 21 years, insiders at Brainstorm Cell Therapeutics have traded over 1,899,994$ worth of Brainstorm Cell Therapeutics stock and bought 1,713,254 units worth 1,535,874$ . The most active insiders traders include Corp. AccbtMike FrankenbergerInternational Holdings Ltd..... On average, Brainstorm Cell Therapeutics executives and independent directors trade stock every 145 days with the average trade being worth of 206,459$. The most recent stock trade was executed by Ibrahim B. Dagher on 19 July 2024, trading 63,000 units of BCLI stock currently worth 22,050$.



What does Brainstorm Cell Therapeutics do?

brainstorm cell therapeutics inc. (nasdaq:bcli), is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as als (lou gehrig's disease), multiple sclerosis (ms) and parkinson’s disease (pd). these diseases have limited treatment options and as such represent unmet medical needs. nurown™ is brainstorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (msc) into neurotrophic factor (ntf)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. our platform technology essentially converts mscs into living drug delivery system for ntfs. we have obtained proof-of-concept in a variety of animal models of neurodegenerative diseases, including parkinson's, huntington's, als, ms, and peripheral nerve injury. we have completed two single-arm clinical trials in als patients, conducted in israel, which have demonstr



What does Brainstorm Cell Therapeutics's logo look like?

Brainstorm Cell Therapeutics, Inc. logo

Brainstorm Cell Therapeutics executives and stock owners

Brainstorm Cell Therapeutics executives and other stock owners filed with the SEC include: